33 related articles for article (PubMed ID: 30131292)
1. Real-world Assessment of Clinical Outcomes in Patients with Metastatic Renal Cell Carcinoma with or Without Sarcomatoid Features Treated with First-line Systemic Therapies.
Sawaya GB; Dragomir A; Wood LA; Kollmannsberger C; Basappa NS; Kapoor A; Soulières D; Finelli A; Heng DYC; Castonguay V; Canil C; Winquist E; Graham J; Bjarnason GA; Bhindi B; Lalani AK; Pouliot F; Breau RH; Saleh R; Tanguay S
Eur Urol Oncol; 2024 Jun; 7(3):570-580. PubMed ID: 38097481
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of mild cognitive impairment and dementia in patients with metastatic renal cell carcinoma.
Miller SM; Wilson LE; Greiner MA; Pritchard JE; Zhang T; Kaye DR; Cohen HJ; Becher RD; Maerz LL; Dinan MA
J Geriatr Oncol; 2022 Jun; 13(5):635-643. PubMed ID: 34996724
[TBL] [Abstract][Full Text] [Related]
3. Association between cognitive impairment and oral anticancer agent use in older patients with metastatic renal cell carcinoma.
Pritchard JE; Wilson LE; Miller SM; Greiner MA; Cohen HJ; Kaye DR; Zhang T; Dinan MA
J Am Geriatr Soc; 2022 Aug; 70(8):2330-2343. PubMed ID: 35499667
[TBL] [Abstract][Full Text] [Related]
4. Disparities in immune and targeted therapy utilization for older US patients with metastatic renal cell carcinoma.
Chow RD; Long JB; Hassan S; Wheeler SB; Spees LP; Leapman MS; Hurwitz ME; McManus HD; Gross CP; Dinan MA
JNCI Cancer Spectr; 2023 May; 7(3):. PubMed ID: 37202354
[TBL] [Abstract][Full Text] [Related]
5. Impact of facility type and volume in low-grade glioma outcomes.
Zhu P; Du XL; Blanco AI; Ballester LY; Tandon N; Berger MS; Zhu JJ; Esquenazi Y
J Neurosurg; 2019 Sep; 133(5):1313-1323. PubMed ID: 31561219
[TBL] [Abstract][Full Text] [Related]
6. Management of metastatic renal cell carcinoma - mini review.
Bharthuar A; Pandey H; Sood S
J Kidney Cancer VHL; 2015; 2(2):75-83. PubMed ID: 28326262
[TBL] [Abstract][Full Text] [Related]
7. Complex surgery and perioperative systemic therapy for genitourinary cancer of the retroperitoneum.
Finelli A; Coakley N; Chin J; Flood TA; Loblaw A; Morash C; Shayegan B; Siemens R
Curr Oncol; 2020 Feb; 27(1):e34-e42. PubMed ID: 32218666
[TBL] [Abstract][Full Text] [Related]
8. Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma Treated With Targeted Therapies: A Systematic Review With a Meta-Analysis.
Petrelli F; Coinu A; Vavassori I; Cabiddu M; Borgonovo K; Ghilardi M; Lonati V; Barni S
Clin Genitourin Cancer; 2016 Dec; 14(6):465-472. PubMed ID: 27138461
[TBL] [Abstract][Full Text] [Related]
9. Prognostic and Predictive Factors for Renal Cell Carcinoma.
Suárez C; Campayo M; Bastús R; Castillo S; Etxanitz O; Guix M; Sala N; Gallardo E
Target Oncol; 2018 Jun; 13(3):309-331. PubMed ID: 29569164
[TBL] [Abstract][Full Text] [Related]
10. The association between facility case volume and overall survival in patients with metastatic renal cell carcinoma in the targeted therapy era.
Chen YW; Ornstein MC; Wood LS; Allman KD; Martin A; Beach J; Gilligan T; Garcia JA; Rini BI
Urol Oncol; 2018 Oct; 36(10):470.e19-470.e29. PubMed ID: 30131292
[TBL] [Abstract][Full Text] [Related]
11. Association Between Treatment at a High-Volume Facility and Improved Survival for Radiation-Treated Men With High-Risk Prostate Cancer.
Chen YW; Mahal BA; Muralidhar V; Nezolosky M; Beard CJ; Den RB; Feng FY; Hoffman KE; Martin NE; Orio PF; Nguyen PL
Int J Radiat Oncol Biol Phys; 2016 Mar; 94(4):683-90. PubMed ID: 26972640
[TBL] [Abstract][Full Text] [Related]
12. Treatment Facility Volume and Survival in Patients with Metastatic Renal Cell Carcinoma: A Registry-based Analysis.
Joshi SS; Handorf EA; Zibelman M; Plimack ER; Uzzo RG; Kutikov A; Smaldone MC; Geynisman DM
Eur Urol; 2018 Sep; 74(3):387-393. PubMed ID: 29880274
[TBL] [Abstract][Full Text] [Related]
13. Predictors, utilization patterns, and overall survival of patients undergoing metastasectomy for metastatic renal cell carcinoma in the era of targeted therapy.
Sun M; Meyer CP; Karam JA; de Velasco G; Chang SL; Pal SK; Trinh QD; Choueiri TK
Eur J Surg Oncol; 2018 Sep; 44(9):1439-1445. PubMed ID: 29935840
[TBL] [Abstract][Full Text] [Related]
14. Comparative Effectiveness of Initial Surgery vs Initial Systemic Therapy for Metastatic Kidney Cancer in the Targeted Therapy Era: Analysis of a Population-based Cohort.
Macleod LC; Odisho AY; Tykodi SS; Holt SK; Harper JD; Gore JL
Urology; 2018 Mar; 113():146-152. PubMed ID: 29174942
[TBL] [Abstract][Full Text] [Related]
15. Is Treatment at a High-volume Center Associated with an Improved Survival for Primary Malignant Bone Tumors?
Malik AT; Alexander JH; Khan SN; Scharschmidt TJ
Clin Orthop Relat Res; 2020 Mar; 478(3):631-642. PubMed ID: 31714413
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]